Figure 3

Rapamycin treatment improves impaired heart function in erbb2 mutant (A) Schematic of experimental design. (B) Quantification of ventricular fractional shortening of control and erbb2^−/− larvae at 3, 5, and 7 dpf (n = 10). (C) Quantification of percent survival over ~2 weeks of control and erbb2^−/− clutchmates from N = 3 tanks of 50 embryos each. (D) Quantification of heart rate in beats per minute of control and erbb2^−/− larvae at 3, 5, and 7 dpf (n = 9–10). (E) Quantification of ventricular fractional shortening of DMSO or rapamycin-treated control and erbb2^−/− larvae at 3, 5, and 7 dpf (n = 9–16). (F) Quantification of heart rate in beats per minute of DMSO or rapamycin-treated control and erbb2^−/− larvae at 3, 5, and 7 dpf (n = 4–11). Data are represented as mean ± SEM. *p = 0.0499, ***p ≤ 0.001, and ****p < 0.0001 by Student’s t test. Note: Asterisk in E indicates a significant difference from 5 dpf rapamycin–treated erbb2^−/−. No significant differences were observed between groups on 3 or 7 dpf.